{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(2)"],"submitter":["Webster CI"],"pubmed_abstract":["The immunogenicity of clinically administered antibodies has clinical implications for the patients receiving them, ranging from mild consequences, such as increased clearance of the drug from the circulation, to life-threatening effects. The emergence of methods to engineer variable regions resulting in the generation of humanised and fully human antibodies as therapeutics has reduced the potential for adverse immunogenicity. However, due to differences in sequence referred to as allotypic variation, antibody constant regions are not homogeneous within the human population, even within sub-classes of the same immunoglobulin isotype. For therapeutically administered antibodies, the potential exists for an immune response from the patient to the antibody if the allotype of patient and antib"],"journal":["mAbs"],"pagination":["253-63"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4966604"],"repository":["biostudies-literature"],"pubmed_title":["A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors."],"pmcid":["PMC4966604"],"pubmed_authors":["Karle AC","Lowe DC","Austin MJ","Spindeldreher S","Cloake EA","Bryson CJ","Jones TD","Webster CI","Baker MP"],"additional_accession":[]},"is_claimable":false,"name":"A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors.","description":"The immunogenicity of clinically administered antibodies has clinical implications for the patients receiving them, ranging from mild consequences, such as increased clearance of the drug from the circulation, to life-threatening effects. The emergence of methods to engineer variable regions resulting in the generation of humanised and fully human antibodies as therapeutics has reduced the potential for adverse immunogenicity. However, due to differences in sequence referred to as allotypic variation, antibody constant regions are not homogeneous within the human population, even within sub-classes of the same immunoglobulin isotype. For therapeutically administered antibodies, the potential exists for an immune response from the patient to the antibody if the allotype of patient and antib","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Feb-Mar","modification":"2025-04-26T14:10:51.326Z","creation":"2019-03-27T02:19:29Z"},"accession":"S-EPMC4966604","cross_references":{"pubmed":["26821574"],"doi":["10.1080/19420862.2015.1128605"]}}